Crinetics Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent in USD from 2016 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Crinetics Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2016 to Q3 2025.
  • Crinetics Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2025 was -$130M, a 69.3% decline year-over-year.
  • Crinetics Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2025 was -$423M, a 52.2% decline year-over-year.
  • Crinetics Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$298M, a 39.1% decline from 2023.
  • Crinetics Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$215M, a 30.9% decline from 2022.
  • Crinetics Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$164M, a 52.3% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)

Crinetics Pharmaceuticals, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$423M -$130M -$53.3M -69.3% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-06
Q2 2025 -$370M -$116M -$41.6M -56.2% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-07
Q1 2025 -$328M -$96.8M -$29.8M -44.6% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-08
Q4 2024 -$298M -$80.6M -$20.5M -34.1% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-27
Q3 2024 -$278M -$76.8M -$19.4M -33.7% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-06
Q2 2024 -$259M -$74.1M -$23.1M -45.3% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-07
Q1 2024 -$235M -$66.9M -$20.9M -45.5% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-08
Q4 2023 -$215M -$60.1M -$15.1M -33.6% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-27
Q3 2023 -$199M -$57.5M -$15.5M -37% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$184M -$51M -$8.6M -20.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$175M -$46M -$11.4M -32.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$164M -$45M -$14.2M -46.1% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-27
Q3 2022 -$150M -$41.9M -$14.1M -50.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$136M -$42.4M -$16.3M -62.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$119M -$34.6M -$11.7M -51.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 -$108M -$30.8M -$9.15M -42.3% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 -$98.5M -$27.9M -$9.53M -52% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$89M -$26.1M -$9.6M -58.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 -$79.4M -$22.9M -$5.54M -31.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$73.8M -$21.6M -$7.09M -48.7% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 -$66.7M -$18.3M -$3.89M -27% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-05
Q2 2020 -$62.8M -$16.5M -$4.06M -32.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 -$58.8M -$17.4M -$8.34M -92.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$50.4M -$14.5M -$6.05M -71.3% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-09
Q3 2019 -$44.4M -$14.4M -$6.84M -90.2% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 -$37.5M -$12.4M -$6.86M -123% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-07
Q1 2019 -$30.7M -$9.02M -$3.55M -65% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q4 2018 -$27.1M -$8.5M -$5.97M -237% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-09
Q3 2018 -$21.1M -$7.59M -$5.21M -219% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-09
Q2 2018 -$15.9M -$5.57M -$3.92M -238% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-09
Q1 2018 -$12M -$5.46M -$2.86M -110% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-09
Q4 2017 -$9.16M -$2.52M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-13
Q3 2017 -$2.38M Jul 1, 2017 Sep 30, 2017 10-K 2019-03-13
Q2 2017 -$1.65M Apr 1, 2017 Jun 30, 2017 10-K 2019-03-13
Q1 2017 -$2.61M Jan 1, 2017 Mar 31, 2017 10-K 2019-03-13

Crinetics Pharmaceuticals, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$298M -$83.9M -39.1% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-27
2023 -$215M -$50.6M -30.9% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-27
2022 -$164M -$56.3M -52.3% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-27
2021 -$108M -$33.8M -45.8% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
2020 -$73.8M -$23.4M -46.4% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-28
2019 -$50.4M -$23.3M -86% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-30
2018 -$27.1M -$18M -196% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-30
2017 -$9.16M -$3.14M -52.1% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-09
2016 -$6.02M Jan 1, 2016 Dec 31, 2016 10-K 2019-03-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.